Glaukos

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. 

CEO
Thomas William Burns
CEOThomas William Burns
Employees
1,094
Employees1,094
Headquarters
Aliso Viejo, California
HeadquartersAliso Viejo, California
Founded
1998
Founded1998
Employees
1,094
Employees1,094

GKOS Key Statistics

Market cap
6.29B
Market cap6.29B
Price-Earnings ratio
-34.27
Price-Earnings ratio-34.27
Dividend yield
Dividend yield
Average volume
651.19K
Average volume651.19K
High today
$109.45
High today$109.45
Low today
$106.50
Low today$106.50
Open price
$109.39
Open price$109.39
Volume
466.34K
Volume466.34K
52 Week high
$130.23
52 Week high$130.23
52 Week low
$73.16
52 Week low$73.16

Stock Snapshot

The current Glaukos(GKOS) stock price is $108.27, with a market capitalization of 6.29B. The stock trades at a price-to-earnings (P/E) ratio of -34.27.

During the trading session on 2026-03-06, Glaukos(GKOS) shares reached a daily high of $109.45 and a low of $106.50. At a current price of $108.27, the stock is +1.7% higher than the low and still -1.1% under the high.

Trading volume for Glaukos(GKOS) stock has reached 466.34K, versus its average volume of 651.19K.

The stock's 52-week range extends from a low of $73.16 to a high of $130.23.

The stock's 52-week range extends from a low of $73.16 to a high of $130.23.

GKOS News

Simply Wall St 3d
Glaukos’ 2025 Loss, Impairment and ESOP Shelf Might Change The Case For Investing In GKOS

In February 2026, Glaukos Corporation reported past fourth-quarter and full-year 2025 results showing sales rising to US$143.12 million for the quarter and US$5...

Glaukos’ 2025 Loss, Impairment and ESOP Shelf Might Change The Case For Investing In GKOS
TipRanks 4d
Glaukos Highlights Interventional Ophthalmology Strategy in Investor Update

Glaukos ( (GKOS) ) has issued an update. Glaukos Corporation released an investor presentation in March 2026 outlining its strategy to transform glaucoma and k...

Analyst ratings

88%

of 16 ratings
Buy
87.5%
Hold
6.3%
Sell
6.3%

People also own

Based on the portfolios of people who own GKOS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.